The report for Middle East and Africa Anti-fungal agents Market of Market Research
Future comprises extensive primary research along with the detail analysis of qualitative
as well as quantitative aspects by various industry experts, key opinion leaders to gain
the deeper insight of the market and industry performance. Anti-Fungal Agents
Market are used in the treatment of fungal infections. According to global action fund for
fungal infection, globally, over 300 billion people of all ages suffer from a serious fungal
infection every year.
The market drivers include rising prevalence of fungal infections, rising awareness, rise
of immunity deficient population such as geriatrics, rise in exposure to infectious agents
due to environmental factors such as pollution especially by particulates and agriculture
residues and climatic conditions such as humidity and temperature, occupational hazards
such as Jock itch, crowding etc. Growth of fungal infection due to off label use of broad
spectrum antibiotics is a prime factor for the growing Anti-Fungal Agents Market.
The market restraints include rising resistance to anti-fungal agents, use of air filters and
air conditioning, excellent spectrum and efficacy of Azole class of anti-fungal agents, loss
of patents and genericitization etc. Competition by generics is exceptionally strong and
generics account for roughly 50% of total sales for anti-fungal agents. The market
penetration is very easy as there has been loss of patents of block buster drugs. Over
the counter drugs are an important reasons for the growth of Anti-Fungal Agents
Market. The Middle East and Africa anti-fungal agents market is led by Azoles followed
by Echinocandins. The Azole class is represented in the market by agents such as
Noxafil, Vfend, and Diflucan.
Among the infections Dermatophytosis holds the majority share followed by candidiasis.
The market leaders with considerable sales include fluconazole, terbinafine, voriconazole,
itraconazole, and caspofungin.
Taking all factors into consideration, we expect the Middle East and Africa Anti-
Fungal Agents Market to reach around $2.85 billion by 2022 from $2.32 billion in
2015, by the end of the forecast period at a CAGR of ~3.5%.
Key Players for Middle East and Africa Anti-fungal agents Market:
Novartis AG, Pfizer, Inc., Sanofi-Aventis, Merck & Co., Inc., Enzon Pharmaceuticals, Inc.,
Bayer AG, Astellas Pharma, Inc., GlaxoSmithKline plc, Abbott, Sigma-Aldrich and others.
Get Sample Copy at https://www.marketresearchfuture.com/sample_request/2582 .
Middle East and Africa Anti-Fungal Agents Market Segments:
Middle East and Africa Anti-Fungal Agents Market has been segmented on the
basis of therapeutic indication which comprises into aspergillosis, dermatophytosis,
candidiasis and others. On the basis of drug class; market is segmented into azoles,
pyrimidines, echinocandins, polyenes, allylamines, and others. On the basis of route of
administration; market is segmented into oral, local and others.
Regional Analysis of Middle East and Africa Anti-fungal agents Market: